Pfizer inks COPD promo deal with Novartis in U.K.; Roche chair says no big mergers;

@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi's dengue shot ups serotype 2 protection rate in final trial. FierceVaccines story | Follow @CarlyHFierce

> Pfizer ($PFE) has signed on to promote two of Novartis' ($NVS) lung drugs, Seebri and Ultibro, in the U.K. Report

> Roche ($RHHBY) Chairman Christoph Franz says the company has ruled out "double-digit billion" deals, but is still open to smaller transactions. Report

> Some drugmakers have bowed out of supplying the Indian government with HIV-fighting drugs because of delayed payments, triggering a shortage. Report

> Fresenius Kabi Oncology, the Indian arm of Germany's Fresenius Kabi, withdrew its petitions asking Indian patent officials to pull IP protections on Pfizer's ($PFE) cancer meds Xalkori and Inlyta. Report

> The Chinese drugmaker Tasly Holding cut the ribbon on its North American operations Wednesday, as part of its plans to expand internationally. Report

> Novo Nordisk ($NVO) cut 63 jobs in Seattle as part of its plans to exit inflammatory drug R&D. Report

Medical Device News

@FierceMedDev: Researchers develop self-powered pacemaker system based on automatic wristwatch. Article | Follow @FierceMedDev

@VarunSaxena2: Per Capita Medicare Spending Is Actually Falling. More from the NYT | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Fingerprint scanning system could help track children's vaccinations in developing countries. More from MIT Technology Review | Follow @EmilyWFierce

> AdvaMed says FDA proposed rule would result in more PMAs, device reclassifications. More

> Four lessons about the orthopedics industry from the CEO of group purchasing organization Amerinet. Editor's corner

> Propeller Health gets $14.5M Series B for smart inhaler, app combo. Article

Biotech News

@FierceBiotech: ICYMI: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Article | Follow @FierceBiotech

@JohnCFierce: In diabetes, everybody is trying to beat everybody on next steps. Which is why Afrezza continues to stand out as a lonely effort. | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. More | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. More | Follow @EmilyMFierce

> Edison's orphan drug misses the mark in Phase II. Story

> Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown. Report

> J&J teams with Bavarian Nordic on an emergency Ebola vaccine program. More

Vaccines News

> FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials. Article

> Study: Old HIV pediatric vaccines might provide protection after all. Item

> Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system. More

> Sanofi's dengue shot ups serotype 2 protection rate in final trial. Story

> Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing. Report

Pharma Manufacturing News

> Theratechnologies returns HIV product Egrifta to U.S. Item

> Wockhardt expects to resolve most FDA concerns within the year. Report

> China sweeps up gang that made and sold 90M toxic capsules. More

> Actavis production not meeting demand for new version of Alzheimer's drug. Story

> Xellia lays out $100M expansion plan for new U.S. facility. Article

And Finally... CVS Health, formerly CVS Caremark, has decided to replace tobacco sales with a smoking-cessation campaign. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…